{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-062451","form_type":"8-K","ticker":"ANVS","cik":"0001477845","company_name":"Annovis Bio, Inc.","filed_at":"2026-05-15T20:00:58+00:00","discovered_at":"2026-05-15T20:03:00.622699+00:00","generated_at":"2026-05-15T20:03:38.102566+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Annovis Bio Q1 net loss $0.63/sh; AD Phase 3 85% enrolled; NDA planned early 2027","bullets":["Net loss per share $0.63 (vs $0.32 in Q1 2025); R&D spend $16.7M (up from $5.0M).","Cash $14.2M at Mar 31, 2026; $10M April offering not included; 28.5M shares outstanding.","Phase 3 AD trial 85% enrolled, full enrollment on track summer 2026; DSMB safety recommendation positive.","PD OLE study 40% enrolled; NDA for buntanetap symptomatic AD treatment expected early 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-062451","json":"https://secwatch.observer/filing/0001104659-26-062451.json","markdown":"https://secwatch.observer/filing/0001104659-26-062451.md","text":"https://secwatch.observer/filing/0001104659-26-062451.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1477845/000110465926062451/0001104659-26-062451-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1477845/000110465926062451/tm2614822d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T20:03:38.102566+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"55f29d491b638dae31f388f1b4a0af8ae23f768b","claim":"Annovis Bio, Inc. reported first quarter ended March 31, 2026 results: EPS $0.63 basic and diluted net loss per common share.","evidence_excerpt":"Annovis reported a $0.63 basic and diluted net loss per common share for the three months ended March 31, 2026, compared to a $0.32 basic and diluted net loss per common share for the three months ended March 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465926062451/0001104659-26-062451-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"EPS","value":"$0.63 basic and diluted net loss per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}